RIDA®QUICK IFX Monitoring

Intended use:

For in vitro diagnostic use. This test is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, Remicade®) and the biosimilars Remsima®, Flixabi® und Inflectra® in human serum und plasma.

General information:

The lateral flow assay RIDA®QUICK IFX Monitoring is a rapid point-of-care assay, which allows for the quantitative determination of infliximab trough levels (TLs) within 20 minutes. It facilitates the use of therapeutic drug monitoring in hospitals and infusion centers and the decision making in regards to therapy adaptation.

• Fast and reliable drug monitoring of infliximab and its biosimilars (Remsima® & Inflectra®)
• Quantitative lateral flow test
• 20 minutes time to result
• High correlation to RIDASCREEN® IFX Monitoring due to identical monoclonal antibody (MA-IFXB7)
• 25 test cassettes per package
• 2 controls available as accessory